Literature DB >> 27251943

Nebivolol and Endothelial Dysfunction in Patients With Essential Hypertension: A Reputation Saver of β-Blockers?

Turgay Celik1, Cengiz Ozturk1, Sevket Balta1, M Ilker Yilmaz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27251943      PMCID： PMC8031517          DOI： 10.1111/jch.12856

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  17 in total

1.  Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.

Authors:  Matthias Oelze; Andreas Daiber; Ralf P Brandes; Marcus Hortmann; Philip Wenzel; Ulrich Hink; Eberhard Schulz; Hanke Mollnau; Alexandra von Sandersleben; Andrei L Kleschyov; Alexander Mülsch; Huige Li; Ulrich Förstermann; Thomas Münzel
Journal:  Hypertension       Date:  2006-08-28       Impact factor: 10.190

2.  Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation.

Authors:  Anna Fratta Pasini; Ulisse Garbin; Maria Cristina Nava; Chiara Stranieri; Anna Davoli; Tatsuya Sawamura; Vincenzo Lo Cascio; Luciano Cominacini
Journal:  J Hypertens       Date:  2005-03       Impact factor: 4.844

3.  Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.

Authors:  R Preston Mason; Ruslan Kubant; Robert F Jacob; Mary F Walter; Bohdan Boychuk; Tadeusz Malinski
Journal:  J Cardiovasc Pharmacol       Date:  2006-07       Impact factor: 3.105

4.  Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil/lymphocyte ratio in patients with newly diagnosed essential hypertension.

Authors:  Francesco Fici; Turgay Celik; Sevket Balta; Atila Iyisoy; Murat Unlu; Sait Demitkol; Halil Yaman; Gianmaria Brambilla; Ejder Kardesoglu; Selim Kilic; Mehemet Yokusoglu; Guido Grassi
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

5.  Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress.

Authors:  Yavuz Baykal; M Ilker Yilmaz; Turgay Celik; Faysal Gok; Hamiyet Rehber; Cemal Akay; I Hakki Kocar
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

6.  Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells.

Authors:  Hanke Mollnau; Eberhard Schulz; Andreas Daiber; Stephan Baldus; Matthias Oelze; Michael August; Maria Wendt; Ulrich Walter; Carolin Geiger; Rahul Agrawal; Andrei L Kleschyov; Thomas Meinertz; Thomas Münzel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-06       Impact factor: 8.311

7.  Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients.

Authors:  Turgay Celik; Atila Iyisoy; Hurkan Kursaklioglu; Ejder Kardesoglu; Selim Kilic; Hasan Turhan; M Ilker Yilmaz; Omer Ozcan; Halil Yaman; Ersoy Isik; Francesco Fici
Journal:  J Hypertens       Date:  2006-03       Impact factor: 4.844

8.  Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist.

Authors:  A Van de Water; W Janssens; J Van Neuten; R Xhonneux; J De Cree; H Verhaegen; R S Reneman; P A Janssen
Journal:  J Cardiovasc Pharmacol       Date:  1988-05       Impact factor: 3.105

9.  The favorable kinetics and balance of nebivolol-stimulated nitric oxide and peroxynitrite release in human endothelial cells.

Authors:  R Preston Mason; Robert F Jacob; J Jose Corbalan; Damian Szczesny; Kinga Matysiak; Tadeusz Malinski
Journal:  BMC Pharmacol Toxicol       Date:  2013-09-28       Impact factor: 2.483

10.  Nitric Oxide Contributes to Vasomotor Tone in Hypertensive African Americans Treated With Nebivolol and Metoprolol.

Authors:  Robert B Neuman; Salim S Hayek; Joseph C Poole; Ayaz Rahman; Vivek Menon; Nino Kavtaradze; David Polhemus; Emir Veledar; David J Lefer; Arshed A Quyyumi
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-08-19       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.